Adrenomyeloneuropathy (AMN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Adrenomyeloneuropathy (AMN) Market Outlook
Thelansis’s “Adrenomyeloneuropathy
(AMN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Adrenomyeloneuropathy (AMN) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Adrenomyeloneuropathy
(AMN) Overview
The
adult-onset of X-linked Adrenoleukodystrophy, called as Adrenomyeloneuropathy
(AMN), is characterized by ABCD1 gene mutation, which results in impaired
peroxisome function with an accumulation of very long chain fatty acids (VLCFA)
and demyelination. Adrenomyeloneuropathy (AMN) is mild, progresses slowly and
is associated with an average life span in the ages of 21-35 years. The main
symptoms include stiffness, weakness, paralysis of the lower limbs and loss of
coordination. Women who are carriers of the disease occasionally experience the
same symptoms along with ataxia, hypertonia, mild peripheral neuropathy and
urinary problems. Individuals with X-ALD who reach their adulthood develop
myelopathy and neuropathy, leading to AMN, in the age group of 30-40 years. The
spinal cord and limber nerves are the only areas that initially exhibit
symptoms. Before MR imaging was available, AMN was often misdiagnosed as
multiple sclerosis or hereditary spastic paraparesis (HSP). In the majority of
cases, this phenotype progresses gradually, resulting in severe motor
disability in the lower limbs over one to two decades, but only mild or no
noticeable deficits in the arms and hands.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment